Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma-Reference-Cited by-同舟云学术

Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

Published:2022-03-23 Issue:11 Volume:128 Page:2148-2158
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Park Sehhoon¹,Oh Dongryul²,Choi Yoon‐La³,Chi Sang Ah⁴,Kim Kyunga⁵,Ahn Myung‐Ju¹^ORCID,Sun Jong‐Mu¹^ORCID

Affiliation:

1. Division of Hematology‐Oncology Department of Medicine Samsung Medical CenterSungkyunkwan University School of Medicine Seoul Republic of Korea

2. Department of Radiation Oncology Samsung Medical CenterSungkyunkwan University School of Medicine Seoul Republic of Korea

3. Department of Pathology and Translational Genomics Samsung Medical CenterSungkyunkwan University School of Medicine Seoul Republic of Korea

4. Department of Health Sciences and Technology Samsung Advanced Institute for Health Sciences and TechnologySungkyunkwan University Seoul Republic of Korea

5. Biomedical Statistics Center Research Institute for Future MedicineSamsung Medical Center Seoul Republic of Korea

Funder

AstraZeneca

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34176

Reference33 articles.

1. Global cancer statistics, 2012

2. Global incidence of oesophageal cancer by histological subtype in 2012

3. Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma

4. Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis

5. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy revolutionizing brain metastatic cancer treatment: personalized strategies for transformative outcomes;Frontiers in Immunology;2024-07-29

2. A novel Phase II single-arm hybrid design to minimize trial duration and enhance subsequent Phase III trial success rate;Journal of Applied Statistics;2024-07-23

3. Immune checkpoint inhibitors and radiotherapy in gastrointestinal cancer treatment;Український радіологічний та онкологічний журнал;2024-07-02

4. Dosimetric comparison of different radial and longitudinal margins for tomotherapy in esophageal cancer;INT J RADIAT RES;2024

5. Current and future perspectives in unresectable locally advanced esophageal squamous cell cancer (Review);Oncology Reports;2024-03-08